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Abstract: Background: Only two, small placebo-controlled trials on peanut- oral immunotherapy
(OIT) have been published. We examined the efficacy, safety, immunological
parameters, quality of life (QoL) and burden of treatment (BoT) of low-dose peanut-
OIT in a multicenter, double-blind, randomized placebo-controlled trial.
Methods: 62 children aged 3-17 years with IgE-mediated, challenge-proven peanut
allergy were randomized (1:1) to receive peanut-OIT with a maintenance dose of 125-
250 mg peanut protein or placebo. The primary outcome was the proportion of children
tolerating ≥300 mg peanut protein at oral food challenge (OFC) after 16 months of OIT.
We measured occurrence of adverse events (AEs), immunological changes, QoL prior
and post OIT and BoT during OIT.
Results: 23/31 (74.2%) children of the active group tolerated at least 300 mg peanut
protein at final OFC compared to 5 /31 (16.1%) in the placebo group (p<.001). 13/31
(41.9%) children of the active versus 1/31 (3.2%) of the placebo group tolerated the
highest dose of 4.5 g peanut protein at final OFC (p<.001). There was no significant
difference between the groups in the occurrence of AE-related drop-outs or in the
number, severity and treatment of objective AEs. In the peanut-OIT group, we noted a
significant reduction in peanut specific IL-4, IL-5, IL10 and IL-2 production by PBMCs
compared to the placebo group, as well as a significant increase in peanut specific-
IgG4 levels and a significant improvement of QoL. 86% of children evaluated the BoT
positively.
Conclusion: Low-dose OIT is a promising, effective and safe treatment option for
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
peanut allergic children, leading to improvement of QoL, a low BoT and immunological
changes showing tolerance development.
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Abstract  64 
Background: Only two, small placebo-controlled trials on peanut- oral 65 
immunotherapy (OIT) have been published. We examined the efficacy, safety, 66 
immunological parameters, quality of life (QoL) and burden of treatment (BoT) of low-67 
dose peanut- OIT in a multicenter, double-blind, randomized placebo-controlled trial.  68 
Methods: 62 children aged 3-17 years with IgE-mediated, challenge-proven peanut 69 
allergy were randomized (1:1) to receive peanut-OIT with a maintenance dose of 70 
125-250 mg peanut protein or placebo. The primary outcome was the proportion of 71 
children tolerating ≥300 mg peanut protein at oral food challenge (OFC) after 16 72 
months of OIT. We measured occurrence of adverse events (AEs), immunological 73 
changes, QoL prior and post OIT and BoT during OIT.  74 
Results: 23/31 (74.2%) children of the active group tolerated at least 300 mg peanut 75 
protein at final OFC compared to 5 /31 (16.1%) in the placebo group (p<.001). 13/31 76 
(41.9%) children of the active versus 1/31 (3.2%) of the placebo group tolerated the 77 
highest dose of 4.5 g peanut protein at final OFC (p<.001). There was no significant 78 
difference between the groups in the occurrence of AE-related drop-outs or in the 79 
number, severity and treatment of objective AEs. In the peanut-OIT group, we noted 80 
a significant reduction in peanut specific IL-4, IL-5, IL10 and IL-2 production by 81 
PBMCs compared to the placebo group, as well as a significant increase in peanut 82 
specific-IgG4 levels and a significant improvement of QoL. 86% of children evaluated 83 
the BoT positively.  84 
Conclusion: Low-dose OIT is a promising, effective and safe treatment option for 85 
peanut allergic children, leading to improvement of QoL, a low BoT and 86 
immunological changes showing tolerance development.  87 
 88 
 89 
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What is known already about the topic?  90 
Only two, small placebo-controlled trials on peanut- oral immunotherapy using a 91 
relatively high maintenance dose of peanut protein have been published so far 92 
showing good efficacy. But safety concerns have been raised. 93 
What does this article add to our knowledge? 94 
With this placebo controlled trial we could show that low-dose oral immunotherapy in 95 
peanut allergic children is effective, has an excellent safety profile, leads to 96 
improvement of quality of life, a low burden of treatment and immunological changes 97 
showing tolerance development. 98 
How does this study impact current management guideline? 99 
Low-dose oral immunotherapy is effective and safe and thus might be a promising 100 
treatment option for peanut allergic children. 101 
Short title 102 
Efficacy, safety and quality of life of low-dose peanut oral immunotherapy in a 103 
placebo-controlled trial  104 
 105 
Abbreviations 106 
AE   Adverse event 107 
BoT   Burden of treatment 108 
FAQLQ-PF/CF/TF Food Allergy Quality of life Questionnaire-Parent/Child/Teenage 109 
form 110 
GI   Gastrointestinal 111 
HRQL   Health-related quality of life 112 
IgE   Immunoglobulin E 113 
IL-4   Interleukin-4 114 
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IQR   Interquartile range 115 
IT   Immunotherapy 116 
ITT   Intention to treat 117 
MCID   Minimum clinical important difference 118 
OAS   Oral allergy syndrome 119 
OFC   Oral food challenge 120 
OIT   Oral immunotherapy  121 
PBMCs  Peripheral blood mononuclear cells 122 
PP   Per protocol 123 
QoL   Quality of life 124 
SAE   Severe adverse event 125 
SCORAD  Scoring Atopic Dermatitis 126 
SPT   Skin prick test 127 
Th2   T helper 2 128 
URI   Upper respiratory infection 129 
 130 
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Introduction 135 
Peanut allergy is a common disease in childhood with estimated prevalence rates 136 
ranging from 0.4% in Europe1 to 3% in Australia2. Ingestion of only small quantities of 137 
the allergen may lead to potentially life-threatening allergic reactions3. Thus peanut is 138 
the most common allergen to induce food-induced anaphylaxis in childhood4. 139 
Patients are advised to strictly avoid peanut but accidental reactions are common 140 
due to widespread use of peanut in the food industry5. Thus, patients are also 141 
advised to carry self-administered epinephrine at all times. Overall, quality of life 142 
(QoL) in patients with peanut allergy is reduced6, 7. Therefore there is a need for an 143 
allergen-specific therapy in this group of patients.  144 
 145 
Recent research has focused on the therapeutic option of oral allergen-specific 146 
immunotherapy. Published trials on peanut oral immunotherapy (OIT) have 147 
demonstrated clinical desensitization of most of the patients, although different doses 148 
for maintenance were used8-18. However, all trials were small and only two were 149 
placebo-controlled. Mild to moderate adverse reactions were reported in the majority 150 
of the patients. Some patients even suffered from anaphylactic reactions associated 151 
to OIT dosing. Although OIT seems an effective treatment option for peanut allergic 152 
patients, safety has to be evaluated more carefully.  153 
 154 
Hypothetically, using a low maintenance dose and a long up-dosing period in peanut-155 
OIT might lead to the same efficacy but better safety profile than using a higher 156 
maintenance dose for a shorter up-dosing period. The aim of this double-blind, 157 
placebo-controlled study was to assess efficacy for clinical desensitization and safety 158 
of OIT as well as possible changes in immunological parameters, in quality of life 159 
after OIT, and the burden of treatment in peanut allergic children using the lowest 160 
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maintenance dose so far reported. It is one of the first placebo-controlled peanut-OIT 161 
trials where oral food challenges (OFC) were conducted prior and post OIT, where a 162 
high enough top dose of peanut protein was included into the final OFC to define a 163 
proper threshold after OIT in individual patients, where safety was assessed 164 
thoroughly and the first where changes in quality of life and burden of treatment 165 
(BoT) were investigated in a placebo-controlled way.  166 
 167 
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Methods 168 
Study overview 169 
This investigator-initiated, multicenter, double-blind, randomized, placebo-170 
controlled, parallel-group trial was conducted at seven German sites (see online 171 
repository, 1.1). We recruited patients consecutively in the outpatient clinics or from 172 
a list of peanut sensitized children followed within these tertiary care clinics. The 173 
study protocol and consent forms were approved by all ethics committees. All 174 
caregivers of the study participants gave written informed consent prior to the start 175 
of the study. The study was registered with the German Clinical Trials Register 176 
(DRKS00004553).  177 
 178 
Study population 179 
Eligible patients were 3 to 17 years of age with a serum peanut-specific IgE >0.35 180 
kU/l and challenge-proven clinically relevant peanut allergy. Parents of the patients 181 
had to be capable of understanding the proposed intervention of the study as well 182 
as being able to follow written emergency instructions. Patients were excluded if 183 
they had participated in another trial, if they were receiving any other form of 184 
immunotherapy including IT using inhalant allergens or if they suffered from a 185 
severe disease (e.g. uncontrolled asthma despite proper treatment). Children with 186 
controlled asthma or a history of severe allergic reaction (severity Grade V 19 like 187 
respiratory arrest, bradycardia, arterial hypotension, cardiac arrest or loss of 188 
consciousness) after peanut consumption were not excluded.  189 
 190 
Study endpoints 191 
This study compared active peanut-OIT with placebo-OIT in children with peanut 192 
allergy. The primary endpoint was defined as the proportion of children tolerating a 193 
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single dose of ≥300 mg peanut protein at final OFC after a maximum of 14 months of 194 
up-dosing and two months of a maintenance phase of OIT in both groups. Secondary 195 
outcomes for efficacy were full clinical desensitization defined as the proportion of 196 
children tolerating the top, single dose of 4.5 g peanut protein at final OFC, median 197 
changes of the maximum tolerated single dose at initial and final OFC and 198 
comparison of the severity of reaction between initial and final OFC. Other secondary 199 
outcomes included safety measurements like severity and number of adverse events, 200 
number of accidental allergic reactions to peanut, change in the severity of other 201 
atopic diseases as well as changes in immunological parameters, quality of life and 202 
the burden of treatment.  203 
 204 
Randomization  205 
After initial OFC, study participants were randomly assigned (1:1) to the active or 206 
placebo group via block randomization with a size of 4 using Dat Inf, Rand List, 207 
version 1.2. A stratification for age (≤ or >6 years) and peanut-specific IgE (≤ or >50 208 
kU/l) was performed by an independent statistician.  209 
 210 
Study design  211 
During the screening visit, the patient’s history was obtained (doctor’s diagnosed 212 
asthma, allergic rhinitis, atopic dermatitis and other primary food allergies), a physical 213 
examination and screening for peanut sensitization was conducted. After 214 
approximately eight weeks, children were admitted to our ward for an open oral 215 
peanut challenge (=initial OFC). After this OFC, patients were eligible to be 216 
randomized. OIT was started the next day on the ward. On the day of the initial OFC 217 
as well as on the day of final OFC - “post OIT” (after the maintenance phase of OIT) - 218 
patients received a physical examination including a SCORAD, a spirometry if 219 
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compliance allowed, a skin prick test (SPT) performed as a prick-to-prick test with the 220 
natural, roasted whole peanut, and blood samples for analysis of B-cell markers 221 
(peanut-, Ara h 2-, timothy-, birch-, mugwort-, dermatophagoides pteronyssinus-, 222 
cladosporium herbarum-, dog- and cat-specific IgE and peanut-specific IgG4 (CAP-223 
System FEIA®, Thermo Fisher)) and T-cell cytokine production in cell culture 224 
supernatants (described in Blumchen et al19). 225 
 226 
Open oral peanut challenges (OFC) 227 
Prior to the start of OIT - at initial OFC - as well as after the maintenance phase at 228 
final OFC children received an open oral peanut challenge using a modified 229 
PRACTALL protocol20 with 2-hour time intervals between dose steps as previously 230 
described19. In summary, patients received whole crushed roasted peanuts in boiled 231 
apple sauce as a matrix in increasing titration steps for a maximum of three days 232 
(first day: 3 mg - 10 mg - 30 mg - 100 mg, second day: 100 mg - 300 mg – 1,000 mg 233 
– 3,000 mg, third day: 4,500 mg peanut protein). The procedure was stopped if 234 
objective clinical symptoms were observed. This dose was considered to be the 235 
eliciting dose. The last single dose the patient tolerated just before the eliciting dose 236 
was defined as the maximum tolerated single dose.  237 
 238 
Procedures for OIT: 239 
Peanut flour (light roasted, 12% fat, 50% protein) from the Byrd Mill Company, 240 
Virginia, USA was used as the peanut protein source for OIT mixed in a vehicle of 241 
chocolate pudding for masking (see online repository, 1.2). The placebo group 242 
received the vehicle without peanut flour. Patients received the first dose of peanut- 243 
/placebo-OIT on the ward. The starting dose of peanut- /placebo-OIT varied 244 
depending on the eliciting dose patients reacted to at initial OFC. If patients had an 245 
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eliciting dose of 3 mg, 10 mg, 30 mg, 100 mg or ≥300 mg peanut protein at initial 246 
OFC they started OIT on a dose of 0.5 mg, 1 mg, 3 mg, 10 mg or 30 mg peanut 247 
protein, respectively. The same OIT dose was administered again the next day. After 248 
two hours of monitoring, patients were instructed to take this dose daily, 249 
approximately at the same time. Up-dosings were planned every two weeks under 250 
medical monitoring in the outpatient clinics of the study centers (see online repository 251 
TABLE E1). The up-dosing phase lasted a maximum of 14 months or shorter if the 252 
patients reached their individual planned maintenance dose. The planned final 253 
maintenance dose was determined by the eliciting dose patients had reacted to at 254 
initial OFC: Patients with an eliciting dose of 3 mg to 100 mg peanut protein at initial 255 
OFC were gradually increased to 125 mg whereas patients with an eliciting dose of 256 
300 mg to 4,500 mg peanut protein were dosed up to 250 mg peanut protein as an 257 
OIT-maintenance dose. The maintenance phase lasted for 8 weeks (+/-2 weeks).  258 
 259 
Safety outcomes 260 
Adverse events (AE) were recorded daily by parents in a diary and were assessed 261 
every one to two weeks by the blinded study physician either during up-dosing visits 262 
or a telephone interview. AEs were recorded as possibly related or related to peanut-/ 263 
placebo-OIT if symptoms occurred within two hours after ingestion. AEs were also 264 
categorized as being either objective (e.g. hives, flush, angioedema, vomiting, 265 
diarrhea, conjunctivitis, rhinitis, sneezing, coughing, wheezing, shortness of breath) 266 
or subjective symptoms (e.g. pruritus, abdominal pain, nausea, oral itching, hawking, 267 
globus sensation or diverse symptoms (joint-, ear- and throat pain, headache, fever). 268 
Severity of possible allergic reactions was determined by the investigator using a 269 
modified grading system for food-induced anaphylaxis19, 21. As judged by the study 270 
physician, AEs were also categorized as being a possible allergic reaction after 271 
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accidental peanut exposure. By assessing the parents’ diary, patient’s spirometry, 272 
peak flow and SCORAD, the study physician determined whether an atopic 273 
comorbidity as asthma, allergic rhinitis and atopic dermatitis improved, worsened or 274 
remained stable during the study on the day of final OFC.  275 
 276 
Health-related quality of life (HRQL) and Burden of treatment (BoT)  277 
To measure changes in health-related quality of life (HRQL), the German translation 278 
of the Food Allergy Quality of Life Questionnaire was sent out to mothers (FAQLQ-279 
PF22, parental form, proxy measurement), children (FAQLQ-CF23, child form) and 280 
teenagers (FAQLQ-TF24, teenage form) 4 weeks before initial OFC and 4 weeks after 281 
final OFC (online repository 1.6). For comparison of changes in HRQL before and 282 
after OIT in both study groups only complete data sets were considered for analysis 283 
(PP analysis). Results represent the median change in total score and each domain 284 
score for each study group prior and post OIT. The greater the negative change in 285 
score the better was the improvement of HRQL.  286 
 287 
The BoT questionnaire was sent out to the families three to four months after starting 288 
OIT. Mothers of children (3-12 years), children (8-12 years) and teenagers (13-17 289 
years) were asked to rate the advantages and disadvantages of OIT-treatment on a 7 290 
point-scale ranging from 1 (=extremely positive) through 4 (=neutral) to 7 (=extremely 291 
negative)25, 26. Mothers and patients were also asked if they would perform OIT 292 
again. Results are presented for each treatment group as numbers of mothers or 293 
children who reported on a positive (score 1-3) or a negative BoT (score 4-7) and 294 
who would and would not perform OIT once more. HRQL- and BoT data of teenagers 295 
were not included in data analysis due to the small number of teenagers within the 296 
study. 297 
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 298 
Statistical Analysis 299 
Values are expressed as median and interquartile ranges [IQR] unless otherwise 300 
indicated, or counts and percentages as appropriate. For primary and secondary 301 
endpoints, data are presented as either proportions or as the median change 302 
between pre- and post-OIT values (median of post-OIT minus pre-OIT values). All 303 
patients randomized were included for the analysis of the primary endpoint as the 304 
intention to treat (ITT) population. For the robustness of the statistical analysis of the 305 
primary endpoint a worst case analysis was also conducted where all drop outs of the 306 
placebo group were considered to reach the primary endpoint and all drop outs of 307 
active group were considered to fail the primary endpoint. Data of the primary 308 
endpoint as well as all other secondary endpoints were also analyzed per protocol 309 
(PP) including all patients who received the intervention and completed the final 310 
OFC. Safety outcomes were analyzed from all patients within the ITT population 311 
receiving at least one dose of placebo-/peanut-OIT, also including all drop out- 312 
patients until the time they discontinued the study. Group comparisons between 313 
randomization arms of continuous variables were performed using the Kruskal-Wallis 314 
test. The primary endpoint and other categorical variables were compared between 315 
randomization arms using the chi-squared test for contingency tables (Fisher exact 316 
test). All statistical tests were 2-tailed, and a two-sided p-value of .05 was considered 317 
for significance. The statistical analyses were performed using R version 2.5.1 318 
(http://www.r-project.org, library Design, Hmisc, ROCR) and Statistical Package for 319 
the Social Sciences (SPSS) version 22.0 (SPSS Inc., Chicago, Illinois, USA).  320 
321 
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Results 322 
 323 
Study population 324 
Of 186 children with suspected peanut allergy approached for the study, 119 refused 325 
to participate, four were tolerant to peanut at initial OFC and the youngest patient 326 
vigorously refused to eat the vehicle (chocolate pudding) (see FIG 1, CONSORT flow 327 
diagram). Thus sixty-two participants with a median age of 6.8 years (range: 3.2 to 328 
17.8 years), median peanut-specific IgE of 81.5 kU/l (range: 0.57-624 kU/l), median 329 
Ara h 2-specific IgE of 44.7 kU/l (range: 0.04- 256kU/l) and median maximum 330 
tolerated single dose at initial OFC of 30 mg peanut protein (range: 1-3,000 mg) were 331 
randomized to receive either active, peanut-OIT (n=31) or placebo-OIT (n=31). Ten 332 
of 62 patients discontinued during the study (see CONSORT diagram): One patient 333 
of the peanut-OIT group withdrew consent after randomization but before receiving 334 
the allocated intervention. This patient was still included in the ITT- analysis (n=62 in 335 
ITT). See FIGURE 1 and the online repository (2.1) for further explanations of all 336 
drop-outs. There were no significant differences between the peanut-OIT and the 337 
placebo group in demographical and immunological baseline characteristics (TABLE 338 
I).  339 
 340 
Efficacy  341 
After a median of 13 months [10-14 months] of the up-dosing and 9.5 weeks [8.5-342 
11.4 weeks] of the maintenance phase, 24 patients of the placebo-OIT and 28 343 
patients of the peanut-OIT group finished the study with a final OFC. 50% in each 344 
randomization group reached their planned maintenance dose. The median 345 
maintenance dose was 125mg peanut protein [50-250mg] in the peanut-OIT and 346 
“125mg placebo” [31.3-225mg] in the placebo-OIT group. Within the ITT population 347 
23 of 31 patients (74.2%) of the peanut-OIT group tolerated ≥300 mg peanut protein 348 
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whereas only 5 of 31 patients (16.1%) within the placebo-OIT group tolerated this 349 
dose at final OFC (p<.001) (TABLE II, FIG 2). Also in the worst-case analysis 350 
(p=0.01) as well as in the per protocol analysis (p<.001) the primary endpoint was 351 
met (TABLE II). As a secondary endpoint, 13 patients of the peanut-OIT group 352 
(41.9% of the ITT population) tolerated the maximum dose of 4.5 g peanut protein at 353 
final OFC compared to only one patient (3.2%) within the placebo-OIT group 354 
(p<.001). With a median of 20 mg [10-100] peanut protein, the maximum tolerated 355 
single dose at final OFC remained unchanged (fold change=1, [0.33-4.3]) when 356 
compared to the median maximum tolerated single dose at initial OFC (30 mg [8.3-357 
100] peanut protein) within the placebo group. In comparison, the maximum tolerated 358 
single dose increased by a factor of 12.1 [4.3-97] from a median of 30 mg [10-300] to 359 
a median of 1,000 mg [825-4,500] peanut protein at final OFC within the peanut-OIT 360 
group.  361 
 362 
Within the first six of eight dose steps of the final OFC the patients of the placebo 363 
group experienced more and more severe reactions than the peanut-OIT group 364 
(FIG3). However, comparing the number of grade IV reactions during all dose steps 365 
(3 mg to 4.5 g peanut protein) at final OFC, there was no difference between the 366 
peanut-OIT (n=7) and placebo group (n=7) (FIG 3).  367 
 368 
Safety 369 
Two patients in each group discontinued due to adverse events (6.5% of the total ITT 370 
population), one of these patients in each group due to a severe adverse event (SAE) 371 
being judged to be related to the OIT dose (FIG 1, for details see online repository 372 
2.1 and TABLE E2). 373 
 374 
 Blumchen  17 
All patients suffered from adverse events (AEs). But only a small number of all 375 
placebo-OIT doses (1.2%) and 4.3% of all peanut-OIT doses were associated with 376 
AEs (=AEs related to OIT = occurring within two hours after OIT-ingestion, TABLE 377 
E2). There was a significantly higher proportion of OIT doses associated with AEs in 378 
the peanut-OIT group than in the placebo-OIT group (p= .001) mainly due to a 379 
significantly higher number of mild, subjective AEs related to peanut-OIT (TABLE 380 
E2). Thus, significantly more patients of the peanut-OIT group (83%) suffered from 381 
subjective AEs related to OIT than patients of the placebo-group (45%) (p= .002). 382 
Especially subjective symptoms like tingling in the mouth, globus sensation, hawking, 383 
and abdominal pain were reported in a significantly higher number in patients 384 
receiving peanut-OIT than in those receiving placebo (TABLE III and E2). None of 385 
the subjective symptoms related to OIT had to be treated.  386 
 387 
More than half of the patients in both groups suffered from objective symptoms within 388 
two hours after ingestion of OIT (TABLE III). However, less than 1% of all OIT doses 389 
were associated with objective symptoms related to OIT (TABLE E2), mainly skin 390 
symptoms (hives and angioedema), vomiting, diarrhea and coughing. There was no 391 
significant difference in the number of OIT doses associated with objective AEs, the 392 
number of patients suffering from objective AEs related to OIT, the severity or the 393 
treatment of these symptoms between randomization groups (TABLE III and E2).  394 
 395 
Regarding individual objective symptoms, wheezing was the only symptom related to 396 
OIT reported significantly more often in the peanut-OIT group (in all eight times by 6 397 
patients) than in the placebo-OIT group (once by one patient, p=0.045) (TABLE III 398 
and E2). However, there was no difference between groups concerning all other 399 
individual symptoms, e.g. coughing or shortness of breath (TABLE III and E2). There 400 
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were more OIT doses associated with objective AEs during the up-dosing phase than 401 
during maintenance, but to a similar extent in both groups (TABLE E2). Dose 402 
reductions due to AEs could be a sign of more severe AEs during OIT. However, 403 
12/30 patients within the placebo-OIT group (40%) and 14/31 patients within the 404 
peanut-OIT group (45%) needed at least one dose reduction due to AEs during the 405 
course of OIT. 406 
 407 
Five patients within the placebo-OIT and three patients within the peanut-OIT group 408 
experienced an SAE (TABLE III and E3). In each group, one patient suffered from an 409 
SAE related to OIT and leading to study discontinuation as mentioned in more detail 410 
in the online repository.  411 
 412 
Within the placebo group, 14 patients experienced 24 allergic reactions which were 413 
considered to be caused by an accidental ingestion of peanut. In contrast, only five 414 
patients of the peanut-OIT group experienced eight accidental reactions (p<.001, 415 
TABLE III).  416 
 417 
After the course of OIT, no difference was found concerning the number of patients in 418 
the two groups with newly diagnosed atopic diseases (bronchial asthma, atopic 419 
dermatitis, allergic rhinoconjunctivitis), with new sensitization to one of the inhalant 420 
allergens tested or with worsening of established atopic diseases at baseline (TABLE 421 
III).  422 
 423 
Immunological parameters  424 
There were no significant differences between the peanut and placebo OIT groups 425 
concerning the baseline levels of immunological parameters (TABLE I, FIG 4). 426 
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Comparing immunological markers within one randomization arm before and after 427 
OIT, a significant reduction in the wheal size of the peanut SPT, peanut specific IL-4, 428 
IL-5, IL10, IL-2, IFN-γ and TNF-α production by PBMCs and a significant increase in 429 
peanut specific-IgG4 levels and decrease of the ratio of peanut specific-IgE to IgG4 430 
could be noted for the peanut-OIT group but not for the placebo-OIT group (FIG 4). 431 
There was no significant change pre/post OIT within one randomization arm for 432 
peanut - and Ara h 2-specific IgE. When comparing the median changes from 433 
baseline between randomization arms, a significant increase in peanut specific-IgG4 434 
and decrease of the ratio of peanut specific-IgE/IgG4 as well as a significant 435 
reduction in IL-4-, IL-5-, IL-10- and IL-2- production could be demonstrated for the 436 
peanut-OIT group in comparison to the placebo-OIT group (FIG 4). There were no 437 
significant differences between groups for the changes of wheal size of peanut SPT, 438 
peanut specific- IgE, Ara h 2-IgE, IFN-γ- and TNF α-production (FIG 4).  439 
 440 
Health-related quality of life (HRQL) and Burden of treatment (BoT)  441 
Before start of OIT, baseline HRQL did not differ between the placebo and active 442 
group in all domains except for the domain of “risk of accidental exposure” in children 443 
(online repository TABLE E4). After final OFC, mothers of both study groups (n=38) 444 
filled out the FAQLQ-PF after a median of 9.5 weeks (IQR [5-15.3]), children (n=17) 445 
filled out the FAQLQ-CF after a median of 11 weeks (IQR [7-16]) after final OFC. 446 
Taking a minimum clinically important difference (MCID) of 0.5 for a significant 447 
clinical improvement of HRQL after an intervention27 mothers of the peanut-OIT but 448 
not the placebo OIT group reported a median improvement of HRQL of greater than 449 
0.5 in score within the domain of “social and dietary limitations” post OIT (FIG 5). 450 
There was no meaningful median change in HRQL reported by mothers within the 451 
total score and the domains of emotional impact and food-related anxiety in the 452 
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placebo group or the peanut-OIT group (FIG 5). However, comparing the placebo 453 
and active group there was no significant group difference in median change in 454 
HRQL for all domains of the FA-QLQ-PF reported by mothers post OIT.  455 
 456 
When children reported on a possible change in HRQL pre and post OIT (FIG 5) the 457 
median improvement for the total score as well as for each domain of the FAQLQ-CF 458 
exceeded the MCID of 0.5 in the peanut-OIT group. Within the placebo group, 459 
median changes ranged between 0 and 0.25. By group comparison, children of the 460 
peanut-OIT group reported a statistically significant improvement in HRQL within the 461 
two domains of “risk of accidental exposure” and “emotional impact” when compared 462 
to the placebo group. 463 
 464 
BoT measures during OIT could be analyzed from 50 of 56 mothers and 21 of 23 465 
children, which were answered a median of 20.5 weeks (IQR [19-23]) after starting 466 
OIT. 22/27 mothers (82%) of the peanut-OIT group and all mothers of the placebo 467 
group (n= 23) reported a positive BoT (=BoT score 1-3). Only one mother from the 468 
peanut-OIT group (3.7%) and two from the placebo group (8.7%) would not perform 469 
OIT again. Nine of eleven children of the active group (82%) and 9/10 children of the 470 
placebo group (90%) were positive about their treatment. One child of each group 471 
spoke against performing OIT again.  472 
473 
 Blumchen  21 
Discussion 474 
Efficacy 475 
This study is the first study to target highly sensitive peanut-allergic patients with a 476 
low-dose peanut OIT in a randomized, placebo-controlled fashion showing a good 477 
efficacy for clinical desensitization, an excellent safety profile, a prevention of 478 
accidental reactions, immunomodulatory capacity, improvement of HRQL and a low 479 
BoT. Efficacy was highly significant with 74% of the active group meeting the primary 480 
endpoint in tolerating a dose of at least 300 mg peanut protein at final challenge in 481 
contrast to only 16% of the placebo group. For the first time ever, we report also on a 482 
significant reduction in the number of accidental reactions during OIT within the 483 
active group (n=8) vs the placebo group (n=24).  484 
 485 
Even with a slow, long-term up-dosing period (median 13 months) and a low 486 
maintenance dose (median 125 mg peanut protein), efficacy in this placebo-487 
controlled trial on peanut-OIT is similar to other studies on OIT using higher 488 
maintenance doses and a shorter up-dosing period, challenging the hypothesis that a 489 
higher maintenance dose may lead to better efficacy. Comparing efficacy for 490 
desensitization in studies on peanut-OIT is difficult because of the variations in 491 
recruited study populations, maintenance doses, duration of up-dosing and 492 
maintenance, and the definition of the endpoint for desensitization.  493 
 494 
However, our result of the primary endpoint is almost equal to two recently published 495 
trials on peanut OIT which recruited a similar risk group of highly peanut allergic 496 
children of a similar age and degree of sensitization, also including children with a 497 
history of anaphylaxis15, 18. Using a higher maintenance dose of 300 mg peanut 498 
protein than in our study, Bird et al reported on 79% of patients within the active 499 
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group tolerating at least 300 mg peanut protein at final challenge in comparison to 500 
19% of the placebo group18. Choosing an even higher maintenance dose of 800 mg 501 
peanut protein, Kukkonen et al were able to demonstrate in a non-controlled trial that 502 
67% of the children in their peanut-OIT group tolerated a maximum cumulative dose 503 
of 1,255 mg peanut protein at final challenge15 which might be comparable to our 504 
results with 68% of the active group tolerating a cumulative dose of 1,443 mg peanut 505 
protein (data not shown) at final OFC. Recently published in a direct comparison, 506 
Vickery et al also demonstrated that using a very high maintenance dose (e.g. 3,000 507 
mg peanut protein) does not lead to a better efficacy than using a lower maintenance 508 
of 300 mg16.  509 
 510 
Interestingly, in this study we could also show that even a lower maintenance dose 511 
than the planned one of 125mg/250mg peanut protein lead to a reasonable efficacy: 512 
Fourteen of the active patients did not reach their planned maintenance dose but had 513 
a median maintenance dose of 50mg peanut protein (range: 2.5- 225mg peanut 514 
protein). Nine of these fourteen (64%) tolerated at least 300mg peanut protein at final 515 
OFC. In contrast, only one of twelve patients of the placebo group who did not reach 516 
their planned maintenance dose reached the primary endpoint with a median 517 
maintenance dose of “32.5mg peanut protein” (FIG E2).  518 
 519 
In choosing the dose of at least 300 mg peanut protein to be tolerated at final OFC as 520 
the primary endpoint we aimed for the protection from severe allergic reactions to 521 
accidental ingestion to peanut in most of the patients within the active group, post 522 
OIT. Recently, Baumert et al demonstrated in a model for quantitative risk 523 
assessment that an increase in the eliciting dose to ≥300 mg peanut protein post OIT 524 
or even more - as in our case to ≥1,000mg as the eliciting dose - would lead to a 525 
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significantly higher and clinically meaningful reduction in the risk of experiencing an 526 
accidental allergic reaction after eating snack chips mixes, cookies, doughnuts or ice 527 
cream in peanut allergic patients28. Our results strengthen this risk assessment. This 528 
is the first report directly demonstrating a protection from accidental reaction by OIT 529 
with a significant reduction in number of accidental reactions within the peanut-OIT 530 
group in comparison to the placebo group (TABLE III). Thus we could demonstrate 531 
that low-dose OIT clinically desensitizes most of the peanut allergic patients to an 532 
extent that they are protected from severe allergic reaction after unintended 533 
exposure.  534 
 535 
This study included fourteen patients who tolerated ≥300mg peanut protein at initial 536 
OFC (TABLE E5). Although receiving a low maintenance dose of only 225- 250mg 537 
peanut protein, this group of patients also seemed to profit from OIT. Eighty percent 538 
of the patients of the active group with a maximum tolerated dose of 300mg peanut 539 
protein and 100% of the active patients tolerating 1,000mg or 3,000mg peanut 540 
protein at initial OFC passed the final OFC with a maximum dose of 4,500mg peanut 541 
protein. Immunological modulation and a reduction of accidental reactions seemed to 542 
occur in the active treated patients. More moderate AEs related to OIT like wheezing 543 
seemed to be a rare event. These results generate the hypothesis that this group of 544 
patients might be a good target population for peanut OIT outside of specialized OIT 545 
centers. But further studies with a larger population with this kind of patients have to 546 
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Similar to other published studies on peanut-OIT8, 10, 11, 29 including the two placebo-551 
controlled trials17, 18, 90% of the patients of the active group suffered from AEs 552 
related to OIT, mainly mild to moderate in severity (Table III). Also, the majority of 553 
these symptoms were of subjective nature. About two thirds of patients in the peanut-554 
OIT group suffered at least once from symptoms of the oral cavity and/or abdominal 555 
pain. However, more than three-quarters of the placebo-group (77%) also 556 
experienced treatment related AEs.  557 
 558 
Comparing the active and placebo groups, there was no difference in the number of 559 
drop outs due to AEs, occurrence of SAEs and occurrence of objective, OIT-related 560 
AEs, in severity of symptoms, treatment of symptoms, or worsening of preexisting 561 
atopic diseases. The only, highly significant difference between the groups could be 562 
demonstrated for the two subjective symptoms of OAS and abdominal pain. 563 
“Wheeze” was the only objective, OIT-related symptom which occurred significantly 564 
more often in the active group versus the placebo group in this study. But with only a 565 
lower significance (p=.04) the clinical significance is debatable since there was no 566 
difference when treatment with salbutamol was analyzed in both groups (TABLE III 567 
and E2).  568 
 569 
Our excellent safety profile might result from the slow up-dosing and the low 570 
maintenance dose used in this protocol. Looking at the proportion of drop outs (13-571 
21%) in other studies recruiting a similar study population but using faster up-dosing 572 
and a higher maintenance dose14, 15, 18 the proportion of drop outs due to AEs (6.7%) 573 
in this study is much lower. There was no need of epinephrine treatment for AEs 574 
related to OIT and absence of development of eosinophilic oesophagitis. Moreover, 575 
antihistamine and steroid treatment was lower than previously reported by others15.  576 
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 577 
Immunological changes  578 
Similar to results published previously, we were able to demonstrate a reduction of 579 
peanut SPT and a marked increase in peanut specific IgG4 post OIT in comparison 580 
to the placebo group8, 16-18. Uniquely, like in our pilot trial8 but now shown for the first 581 
time in comparison to a placebo-group, we again found not only an in vitro peanut-582 
specific suppression of Th-2 cytokines such as IL-4 and IL-5 but also a general 583 
suppression of cytokine production for IL-2, IL-10, IFN-γ and TNF-α in the peanut-584 
OIT group post OIT. No change was noted in the placebo-OIT group. Similar results 585 
for the possible induction of anergy but not for a shift to Th1 cytokine upregulation 586 
were also reported by Gorelik et al.30. They demonstrated a reduction of IL-5-, IL-13, 587 
but also of IFN-γ-, IL-10- and TNF-α-production of CD4+ T cells co-cultured with 588 
myeloid dendritic cells after 12 months of a maintenance peanut OIT with 2 g of 589 
peanut protein ingested daily.  590 
 591 
Health-related quality of life (HRQL) and Burden of treatment (BoT)  592 
After peanut-OIT there was a significant improvement in HRQL (decrease in score) 593 
for the domain of “risk of accidental exposure” and “emotional impact” in children 594 
when compared to the placebo group approximately 11 weeks after final OFC. If one 595 
considers an improvement of >0.5 MCID as significant27, the HRQL even improved 596 
for all domains in children and for the domain of “social and dietary limitations” in 597 
mothers’ proxy reports of the active group. This is the first trial on OIT showing a 598 
significant improvement of HRQL after OIT in a placebo-controlled study design. Two 599 
previously published studies on peanut-OIT showed a significant improvement of 600 
HRQL post OIT in parents’ proxy reports13, 31 and in children and teenagers reports31 601 
using the same questionnaires but not comparing their results to a control group.  602 
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 603 
To our knowledge, this is the first time that BoT has been analyzed for an OIT study. 604 
Although patients and parents had to cope with a daily therapy which might have also 605 
elicited disgust, AEs and included also a daily two-hour interval of parental monitoring 606 
of their children, the majority of mothers and children reported (after a median of four 607 
months on OIT) being positive (=low BoT) about this treatment and would start this 608 
kind of therapy again.  609 
 610 
Limitations of this study  611 
Since an unblinded OFC protocol was used in this study overreporting of allergic 612 
reactions during baseline OFCs and underreporting at final OFCs due to change of 613 
attitude of the children towards peanut ingestions might have occurred. However, 614 
efficacy results are so robust and similar to other efficacy data on peanut-OIT 615 
published so far15, 18 this effect seems marginal. Additionally, the OFC protocol used 616 
in this study- with a two-hour interval between dose steps19- differs from other OFC 617 
protocols used in OIT trials possibly changing the sensitivity of threshold and severity 618 
of reactions during OFC which might impact the efficacy data of this trial. However, 619 
the eliciting dose for peanut-induced allergic reactions in 5% of this study population 620 
(ED05)19 is comparable to the ED05 of other published peanut allergic populations 621 
being challenged with 15 to 30 minute intervals32-34. Therefore the sensitivity for 622 
threshold might not be too different to other published studies on peanut OIT. Due to 623 
differences in the reporting of the severity of reaction during OFC the data of this 624 
current study cannot be compared to others. Therefore it might well be that due to a 625 
two hour interval between dose steps more severe reactions could have been 626 
avoided.   627 
  628 
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Summary 629 
In conclusion, we have been able to demonstrate for the first time in a placebo-630 
controlled way that using a low maintenance dose in peanut OIT has a very good 631 
safety profile with an efficacy similar to that reported by other studies using higher 632 
maintenance doses. Treatment with low-dose peanut-OIT leads to immunological 633 
changes, pointing to the possible development of immunological anergy due to OIT. 634 
Despite daily treatment and daily monitoring for two hours, children showed a 635 
significant improvement in HRQL post OIT, which was demonstrated here for the first 636 
time in a placebo-controlled manner. Furthermore, overall BoT seems to be very low 637 
for this kind of therapy. However, further placebo-controlled, long-term studies with a 638 
larger number of patients, especially including more teenagers, are needed to verify 639 
the reduction of allergic reaction after accidental exposure due to OIT and to further 640 
evaluate safety. 641 
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Age (years), median [IQR] 7.9 [4.6-10.7] 6.6 [4.8-9.8] 
Sex, male, n (%) 19 (61.3) 19 (61.3) 
Weight (kg), median [IQR] 22.4 [18.2-36.4] 24.0 [18.7-31.8] 
Positive family history of atopy, n (%) 29 (93.5) 26 (83.9) 
Asthma/ increased airway reactivity, n (%) 20 (64.5) 13 (41.9) 
Atopic dermatitis, n (%) 22 (71) 19 (61.3) 
Allergic rhinitis, n (%) 18 (58.1) 14 (45.2) 
Further systemic food allergies+, n (%) 12 (38.7) 9 (29) 
History for accidental allergic reaction to peanut and to unknown 
cause, n (%) 
29 (93.5) 31 (100) 
History of accidental allergic reaction to peanut and to unknown 
cause with severity grade ≥IV ++ n (%)  
16 (51.6) 18 (58.1) 
Eliciting single dose of peanut protein (mg) at initial OFC,  
median [IQR] 
100 [10-200] 100 [30-1000] 
Cumulative eliciting dose (mg peanut protein) consumed at day 
of allergic reaction of OFC, median [IQR] 
143 [13-272] 143 [43-1400] 
Maximum tolerated single dose of peanut protein (mg) at initial 
OFC, median [IQR] 
30 [3-65] 30 [10-300] 
Patients tolerating ≥ 300 mg peanut protein at initial OFC+++, n (%) 4 (12.9) 10 (32.3) 
Severity++ of reaction at OFC, n (%):                                       Grade I 1 (3.2) 1 (3.2) 
                                                                                                       Grade II 13 (41.9) 11 (35.5) 
                                                                                                       Grade III 11 (35.5) 10 (32.3) 
                                                                                                       Grade IV 6 (19.4) 9 (29) 
Peanut SPT (mm), median [IQR] 8 [7-9.8] 8 [6.5-9.5] 
Total IgE (kU/I), median [IQR] 434 [267-758] 347 [193-766.5] 
Peanut specific-IgE (kU/I), median [IQR] 73.1 [31.3-197] 89.5 [6.9-217] 
Ara h 2 specific-IgE (kU/l), median [IQR] 48.8 [20.5-85.7] 44.6 [6.4-99.7] 
Peanut specific-IgG4 (mgA/l), median [IQR] 0.38 [0.15-0.97] 0.63 [0.18-0.89] 
 658 
Continuous values are presented as medians with interquartile range. Kruskal-Wallis 659 
test was used for statistical analysis. Categorical variables are presented as number 660 
of participants and percentage using the chi-squared test for statistical analysis.  661 
+defined as either historical or challenge proven systemic reaction to food allergens 662 
other than peanut,  663 
++ for detailed definition of grading the severity of allergic reactions see Blumchen et 664 
al.19, 665 
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+++ number of patients with an eliciting single dose of 1 g, 3 g or 4.5 g peanut protein 666 
at initial OFC 667 
  668 
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TABLE II: Clinical efficacy endpoints 669 
 placebo-OIT peanut-OIT p values 
Primary endpoint: 
 






Patients tolerating ≥300 mg peanut protein at final 
OFC, n (%) 
5 (16.1) 23 (74.2) <.001 
Patients newly tolerating ≥300 mg peanut protein at 
final OFC*, n (%) 
1 (3.2) 13 (41.9) <.001 
 






Patients tolerating ≥300 mg peanut protein at final 
OFC, n (%) 
12 (38.7) 23 (74.2) .01 
 






Patients tolerating ≥300 mg peanut protein at final 
OFC, n (%) 










Patients tolerating the maximum dose of 4,500 mg 
peanut protein at final OFC, n (%) 
1 (3.2) 13 (41.9) <.001 
 






Patients tolerating the maximum dose of 4,500 mg 
peanut protein at final OFC, n (%) 
1 (4.2) 13 (46.4) .002 
Maximum tolerated single dose of peanut protein 
(mg) at final OFC, median [IQR] 
20 [10-100] 1000 [825-4500] <.001 
Change in maximum tolerated single dose of peanut 
protein (mg) at final OFC, median [IQR] 
0 [-7.5-13.5] 997 [592.5- 4200] <.001 
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 670 
Data presents the primary and secondary clinical endpoints within the intention to 671 
treat (ITT) and per protocol (PP) population. For primary and secondary clinical 672 
endpoints data is presented as proportions of patients within one randomization arm 673 
at final OFC post OIT and was statistically analyzed by using the chi-squared test for 674 
contingency tables (Fisher exact test). Within the PP population the median change 675 
of maximum tolerated peanut dose between initial OFC and final OFC was calculated 676 
and statistically analyzed using the Kruskal-Wallis test. For analysis of the primary 677 
endpoint a worst-case imputation was also used. * Number of patients who did not 678 
tolerate ≥ 300 mg peanut protein (single eliciting dose of 3-300 mg) at initial OFC but 679 
tolerated it at final OFC.  680 
  681 
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TABLE III: Patients with adverse events (AEs) related to OIT in the placebo-OIT 682 







Total number of adverse events (AEs), n=(%*) 
2,866 (20.7) 2,515 (20.3) .71 
Total number of severe adverse events (SAEs), n=(%*) 
5 (0.04) 3 (0.02) .73 
Number of SAEs related to OIT,  n=(%*) 
1 (0.007) 1 (0.008) 1.0 
Number of patients who discontinued the study due to 
AEs,  n=(%**) 
2(6.5) 2 (6.7) 1.0 
 
 




AEs related to OIT, n= (%**) 
24 (77.4) 27 (90) .3 
subjective AEs related to OIT, n= (%**) 
14 (45.2) 25 (83.3) .002 
OAS related to OIT, n= (%**) 8 (25.8) 18 (60) .007 
abdominal pain related to OIT, n= (%**) 6 (19.4) 20 (66.7) <.001 
nausea related to OIT, n= (%**) 2 (6.5) 7 (23.3) .06 
skin itching related to OIT, n= (%**) 7 (22.6) 7 (23.3) .94 
joint pain/ headache/ throat pain related to OIT, n= (%**) 2 (6.5) 6 (20) .12 
objective AEs related to OIT, n= (%**) 
21 (67.7) 19 (63.3) .72 
skin symptoms related to OIT (contact urticarial, flush, 
generalized hives, angioedema), n= (%**) 
8 (25.8) 12 (40) .24 
GI symptoms related to OIT (vomiting, diarrhea), n= (%**) 
7(22.6) 8 (26.7) .71 
URT symptoms related to OIT (conjunctivitis, rhinitis, 
sneezing, rhinoconjunctivitis), n= (%**) 
10 (32.3) 9 (30) .85 
laryngeal symptoms related to OIT (hoarseness, stridor), 
n= (%**) 
1 (3.2) 1 (3.3) .98 
lower respiratory tract symptoms related to OIT (coughing, 
wheezing, shortness of breath), n= (%**) 
9 (29) 13 (43.3) .25 
coughing related to OIT, n= (%**) 
6 (19.4) 11 (36.7) .13 
wheezing related to OIT, n= (%**) 
1 (3.2) 6 (20) .04 
shortness of breath related to OIT, n= (%**) 
4 (12.9) 3 (10) .72 
cardio-vascular symptoms (drop in blood pressure, 
unconsciousness) related to OIT, n= (%**) 
1 (3.2) 0 (0) 1.0 
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 684 
Data presents the occurrence of adverse events and the number of patients with AEs 685 
related to OIT during the study in both randomization groups. Severity was graded 686 
using a modified grading system for food-induced anaphylaxis19, 21.  687 
Adverse event (AE), Severe Adverse Event (SAE), Oral allergy syndrome (OAS), GI 688 
(Gastro-intestinal), Upper respiratory tract (URT). 689 
*% of all OIT doses within randomization group, ** % of all patients within the 690 
randomization group. 691 
  692 
AEs related to OIT of severity grade I, n= (%**) 
5 (16.1) 7 (23.3) .48 
AEs related to OIT of severity grade II, n= (%**) 
10 (32.2) 11 (36.7) .72 
AEs related to OIT of severity grade III, n= (%**) 
13 (41.9) 10 (33.3) .49 
AEs related to OIT of severity grade IV, n= (%**) 
4 (12.9) 7 (23.3) .29 
AEs related to OIT of severity grade V, n= (%**) 
1 (3.2) 0 (0) .32 
Treatment for AEs related to OIT, n= (%**) 
9 (29) 12 (40) .37 
Systemic antihistamines for AEs related to OIT, n= (%**) 
6 (19.4) 8 (26.7) .55 
Systemic steroids for AEs related to OIT, n= (%**) 
4 (12.9) 4 (13.3) 1.0 
 Inhalant salbutamol for AEs related to OIT, n= (%**) 
5 (16.1) 6 (20) .69 
Adrenalin for AEs related to OIT, n= (%**) 
0 (0) 0(0) 1.0 


















Accidental reactions, total n= (average per person) 
24 (0.77) 8 (0.27) <.001 
Number of patients with accidental reactions, n= (%**) 
14 (45.2) 5 (16.7) .026 
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Figure Legends 693 
 694 
Fig 1  CONSORT diagram.  695 
 696 
Fig 2  Maximum tolerated single dose of peanut protein prior and post OIT. 697 
Shown are the maximum tolerated single doses of peanut protein at initial and final 698 
OFC in (A) individual placebo-OIT patients and (B) peanut-OIT patients of the per 699 
protocol population. The horizontal lines represent the median of the maximum 700 
tolerated single dose in each group. For the statistical analysis of the comparison of 701 
data pre and post treatment within one randomization group, the Wilcoxon-test was 702 
used. **p<.01 703 
 704 
Fig 3  Grade of severity of allergic reactions during final OFC at individual dose 705 
steps. Shown are the proportions of patients of (A) the placebo-OIT and (B) the 706 
peanut-OIT group with their individual severity of symptoms at each dose step during 707 
final OFC within the per protocol population. Severity was graded using a modified 708 
grading system for food-induced anaphylaxis19, 21. 709 
OFC, oral food challenge 710 
 711 
Fig 4  Immunological changes from baseline (pre OIT) to post OIT at final OFC 712 
of the per protocol population. Shown are wheal size diameter of peanut SPT (A), 713 
peanut specific-IgE (B), Ara h 2 specific-IgE (C), peanut specific-IgG4 (D), ratio of 714 
peanut specific-IgE/peanut specific-IgG4 (E), IL-4- (F), IL-5- (G), IL-10- (H), IL-2- (I), 715 
IFN-γ- (J) and TNF-α production (K) after in vitro stimulation of PBMCs with peanut 716 
extract minus the amount of cytokine production after stimulation with medium. Black 717 
lines represent median values. Black circles/ squares represent patients tolerating a 718 
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maximum dose of up to 100mg, orange circles/squares represent patients tolerating 719 
a maximum dose of 300 to 3,000mg and green circles/squares represent patients 720 
tolerating a maximum dose of 4,500mg peanut protein at final OFC. For the statistical 721 
analysis of the comparison of data pre and post treatment within one randomization 722 
group the Wilcoxon-test was used. For the intergroup comparison the median 723 
changes from baseline in each group were calculated and analyzed by the Kruskal-724 
Wallis test (*p<.05; **p<.01; ***p<.001).  725 
 726 
FIGURE 5  Change in HRQL after OIT. Presented is the median change in total and 727 
each domain score for the FA-QLQ CF (child form) and FA-QLQ PF (parent form) for 728 
each study group after OIT in the per protocol population. Open symbols represent 729 
the placebo group, filled symbols the peanut-OIT group, dotted the minimum clinical 730 
important difference (MCID). The greater the negative change in score the better is 731 
the improvement of HRQL. The Kruskal-Wallis test was used for a group comparison. 732 
p= statistical significance, bold values represent a significant change in HRQL after 733 
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1. Supplemental Methods 28 
1.1 Study centers 29 
Dept. of Pediatric Pneumology, Immunology and Intensive Care Medicine, Charité 30 
Universitätsmedizin Berlin, Berlin, Germany; Children’s Hospital “Altona”, Hamburg; 31 
Dept. of Pediatrics, Technical University Munich, Munich; Dept. of Pediatrics, Ruhr-32 
University Bochum, Bochum; Dept. of Pediatric Pneumology, Allergology and 33 
Neonatology, Hannover Medical School, Hannover;  Department of Pediatrics and 34 
Adolescent Medicine, University Medical Center, Medical Faculty, University of 35 
Freiburg, Freiburg, Germany; Dept. of Pediatrics, University Hospital Carl Gustav 36 
Carus, Technical University of Dresden, Dresden 37 
 38 
1.2 Preparation and dosing of oral immunotherapy 39 
For proper blinding of OIT, a special chocolate pudding vehicle was used during this 40 
study developed by the EuroPrevall project1. Initially it was developed by the Institute 41 
of Food Research (Norwich, UK) based on a system devised by Unilever R&D BV 42 
(Vlaardingen, Netherlands). It is a well standardized vehicle and shows good 43 
reproducibility, homogenicity, blinding capacities and a long shelf life (up to 6 months 44 
as the pudding base). Three sets of chocolate peanut/placebo pudding bases were 45 
produced every 4-5 months :((1) “high dose”- recipe (5mg peanut protein/ml in final 46 
“ready to eat” pudding), (2) “low dose”- recipe (1mg peanut protein/ml in final “ready 47 
to eat” pudding) and (3) an allergen free recipe (placebo)). All materials for the 48 
pudding bases were stored in a microbiologically stable manner. The pudding bases 49 
during the study were prepared in a food-grade environment (the main hospital 50 
kitchen of the Charité, Berlin). All equipment was thoroughly washed with detergent 51 
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before use so that any dust or allergenic material was removed. The following 52 
ingredients were used for the chocolate pudding bases: cold swelling starch (ULTRA-53 
TEX 4, National Starch, Hamburg, Germany), cocoa powder (Cebe Cacao, lightly 54 
defatted, Wilhelm Reuss, Berlin, Germany), rapeseed oil (Karl Heidenreich GmbH; 55 
Mannheim, Germany), icing sugar (sweet family Nordzucker, Braunschweig, 56 
Germany), sweetener (Huxol, Nutrisun, Seevetal, Germany), TweenTM 60 (Croda, 57 
Singapore). As the vehicle contains TweenTM 60 (polysorbat 60, E435), therefore all 58 
study participants had to weigh at least 13 kg. Peanut flour (light roasted, 12 % fat, 59 
50% protein) from Byrd Mill Company, Virginia, USA was used as the peanut protein 60 
source. 128.57g of the chocolate peanut/placebo pudding bases was transferred into 61 
a container and was stored in a cool dark condition (20oC) for up to 6 months. 62 
 63 
Before distribution to the patient, the microbiological safety of each batch of the 64 
chocolate peanut/placebo pudding base was checked by Institute Fresenius (Berlin, 65 
Germany) according to national and international standards. Testing included total 66 
bacterial counts, tests for yeasts, moulds and lactic acid bacteria as well as 67 
surveillance for indicator microorganisms (Enterobactereriacae, sulphite-reducing 68 
clostridia) and pathogens (Salmonella spp, Bacilli spp, S. aureus, C. perfringens,  69 
Listeria monocytogenes, E. coli, Campylobacter spp., Vibrio cholerae, Y. 70 
enterocolitica). Each batch was also tested for peanut protein quantification and 71 
homogeneity verification determining the allergen-free status of the chocolate 72 
placebo pudding, the homogeneity of the chocolate peanut pudding and the stability 73 
of protein doses between batches.  74 
Every 7 to 14 days, parents had to prepare the “ready to eat”, hydrated pudding 75 
themselves. Parents were thoroughly instructed and taught how to prepare the “ready 76 
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to eat pudding” to ensure good homogeneity. They had to pour 300 ml of bottled 77 
water into each container of the pudding bases and mix it thoroughly with an electric 78 
mixer. This freshly made pudding was divided into smaller portions which were then 79 
frozen at home for a maximum of 40 days. Every two days one storage box of frozen 80 
“ready to eat” pudding was defrosted. The patient’s individual dose of pudding was 81 
measured using different sized spoons. The volumes were exact if the whole spoon 82 
was filled with the pudding, and levelled off by a flat edge knife and extra pudding 83 
being removed from the sides. The exact dosing schedule is outlined in TABLE E1. 84 
 85 
TABLE E1  Dosing schedule of “ready to eat”-chocolate peanut/placebo 86 
pudding for OIT 87 
 88 




















1 1.0 2.0 0.5 0.5 0 
2 1.0 4.0 1.0 1.0 0 
3 1.0 6.0 1.5 1.5 0 
4 1.0 10.0 2.5 2.5 0 
5 1.0 12.0 3.0 3.0 0 
6 1.0 14.0 3.5 3.5 0 
7 1.0 18.0 4.5 4.5 0 
8 1.0 22.0 5.5 5.5 0 
9 1.0 26.0 6.5 6.5 0 
10 1.0 32.0 8.0 8.0 0 
11 1.0 38.0 9.5 9.5 0 
12 1.0 44.0 11.0 11.0 0 
13 1.0 52.0 13.0 13.0 0 
14 1.0 60.0 15.0 15.0 0 
15 1.0 70.0 17.5 17.5 0 
16 1.0 80.0 20.0 20.0 0 
17 1.0 90.0 22.5 22.5 0 
18 1.0 100.0 25.0 25.0 0 
19 1.0 120.0 30.0 30.0 0 
20 5.0 140.0 35.0 7.0 0 
21 5.0 160.0 40.0 8.0 0 
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22 5.0 180.0 45.0 9.0 0 
23 5.0 200.0 50.0 10.0 0 
24 5.0 240.0 60.0 12.0 0 
25 5.0 280.0 70.0 14.0 0 
26 5.0 340.0 85.0 17.0 0 
27 5.0 420.0 105.0 21.0 0 
28 5.0 500.0 125.0 25.0 0 
29 5.0 600.0 150.0 30.0 0 
30 5.0 700.0 175.0 35.0 0 
31 5.0 800.0 200.0 40.0 0 
32 5.0 900.0 225.0 45.0 0 
33 5.0 1,000.0 250.0 50.0 0 
 89 
 90 
1.3 Peanut protein quantification and homogeneity testing of 91 
pudding bases  92 
Using a Kjeldahl total nitrogen method2, 51.0 % (0.6% CV) total protein was 93 
determined in defatted peanut flour (Byrd Mill Company, Virginia, USA) used for the 94 
preparation of low and high dose dessert bases, confirming the  manufacturer’s 95 
information of a total protein content of 50% within the peanut flour. Accordingly, for 96 
further investigation of peanut protein quantity and homogeneity using ELISA, 50% 97 
peanut protein in peanut flour was assumed. Thus, according to the recipe, the high 98 
and low dose pudding bases should contain 1.7 % or 0.34% peanut protein, 99 
respectively. Using a previously described peanut-specific ELISA3, the presence and 100 
quantity of peanut protein was investigated in 10 placebo batches, 11 low dose 101 
pudding bases, and 15 high dose pudding bases. From each of these, a total of ten 102 
4 g sub-samples were randomly drawn, individually extracted, and analysed in each 103 
triplicate dilution and triplicate wells per dilution. In placebo pudding bases, peanut 104 
protein was not detectable (with a limit of detection of 0.1 ppm or 0.00001 % peanut 105 
protein). Considering that final, “ready to eat” chocolate pudding portions are made of 106 
1:3.333 dilution of pudding base in water, peanut protein is absent or below 0.03 ppm 107 
in placebo meals. As a worst case calculation, peanut protein at the limit of detection 108 
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would theoretically translate to a peanut protein dose of 1.5 µg for the largest portion 109 
(50 ml) given to patients. 110 
With a median recovery (ratio of protein quantified and protein added according to 111 
recipe) of 88% (range 73 – 115 %), the amount of peanut protein of 0.34% and 1.7% 112 
was analytically confirmed in all batches of low and high dose pudding (FIG E1 a). 113 
Further, all batches of high dose pudding showed homogeneous distribution of 114 
peanut protein with mean CV < 15 % (FIG E1 b). In 10/11 low dose pudding bases a 115 
homogeneous peanut protein distribution with mean CV < 15 % was determined. 116 
With 15.3 % CV in 1/11 low dose dessert bases the upper limit of the 95%- 117 
confidence interval slightly exceeded the set limit of 15 % mean CV but was still 118 
interpreted as presenting acceptable homogeneity. Statistical significance was 119 
achieved in the majority of cases with p < .0001. For this above described batch and 120 
all following batches patients had to step one step down in their dosing schedule and 121 
be monitored when consuming a new batch for the first time. Ready-to eat chocolate 122 
pudding stored frozen showed 91.5 % of detectable peanut protein compared to 123 
freshly made chocolate pudding. 124 
 125 
Fig E1    126 














































FIG E1  Peanut protein quantification and homogeneity in different batches of 130 
low dose and high dose pudding bases 131 
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Box plot analysis of low dose (1) and high dose (2) pudding bases. Percentage of 132 
peanut protein quantified (a), and variation of homogeneity expressed as mean % CV 133 
(b). CV= coefficient of variation 134 
  135 
1.4 Statistical analyses: power calculation 136 
For the primary endpoint, efficacy rates were assumed to be 65% in the peanut-OIT 137 
group and 15% in the placebo-OIT group on the basis of our previously published 138 
data4. With an assumed drop out-rate of 20%, a target sample size of 56 patients 139 
(randomized 1:1 to both groups) was calculated to provide at least 90% power 140 
(α/2=0.025, one-sided Fisher-exact test). 141 
 142 
 143 
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1.5 Standard operating procedures (SOPs) for safety 144 
During the inpatient phase (at challenge and start of OIT) emergency training for the 145 
emergency kit was repeated. The emergency kit included two epinephrine auto- 146 
injectors, oral antihistamine, an oral corticosteroid or suppository, and beta2-agonist 147 
for inhalation. Families were advised that the kit should be available at all times. A 148 
24-hour-telephone hotline by medical doctors was available to answer questions 149 
regarding dosing and AEs. Parents were instructed to monitor their children for two 150 
hours after the intake of peanut- /placebo-OIT. Patients were advised to avoid 151 
strenuous physical activity during this time, to carry the emergency medication (e.g. 152 
two epinephrine auto-injectors) at all times and to strictly avoid peanuts otherwise. 153 
 154 
Reasons and procedure for OIT-dose reductions: 155 
 If symptoms were considered to be a viral or bacterial infection, the advice 156 
was to continue with 50% of the previous daily OIT dose. This 50% of the dose 157 
was given for three days, followed by another three days with 75% of the 158 
dose. After that the full dose could be ingested again (i.e. “dosing scheme for 159 
infections”). This reduction and up-dosing was done at home. Patients had to 160 
be stable on this dose for further 14 days until another up-dosing to a new 161 
dose could occur in the clinic. 162 
 If symptoms were considered to be due to an accidental reaction or the patient 163 
received a vaccination or an elective operation, the OIT-dose was skipped that 164 
day and for the following days the “dosing scheme for infections” was applied. 165 
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 For safety reasons doses were reduced by one dose- step if a new charge of 166 
chocolate peanut/placebo- pudding bases was used.  167 
 If a mild related or non-related AE (severity grade I) or a mild AE at up-dosing 168 
or a subjective AE occurred, the same dose was given the next day at home.  169 
 If an objective, moderate related AE (severity grade II-IV) or an objective, 170 
moderate AE at up-dosing occurred, either the “dosing scheme for infections” 171 
or a reduction of dose (one step down) was applied at home as determined by 172 
the study physician. The subsequent up-dosing was performed in the study 173 
center. 174 
 If a moderate non-related AE (severity grade II-IV) occurred, either the “dosing 175 
scheme for infections” or a reduction of dose (one step down) was applied or 176 
the same dose was given for another 14 days before up-dosing. 177 
 If recurrent mild related or recurrent non-related AEs (especially GI symptoms) 178 
were detected, the dose was reduced by one step. 179 
 If recurrent related or non-related pulmonary symptoms at a certain dose 180 
occurred a more vigorous dose reduction was performed (2 to 12 dose steps 181 
down) as was determined by the study physician. The doses were then 182 
increased every 14 days at home until the former dose was reached. 183 
 184 
Early termination of the treatment:  185 
 OIT-treatment was terminated if a patient showed objective symptoms related 186 
to OIT (within two hours of OIT dose) repeatedly, every time the dose was 187 
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increased above a certain level. A maximum of three trials for up-dosings were 188 
tried before early termination was considered. 189 
 OIT-treatment was terminated if there was a serious adverse event (SAE) 190 
related or possibly related to OIT. This was defined as an SAE occurring within 191 
two hours of OIT ingestion. Events were categorized as SAEs if they were life-192 
threatening, resulted in any kind of hospitalization (included if only for 193 
monitoring), disability, congenital anomaly and death or were otherwise 194 
deemed an important medical event. 195 
 OIT-treatment was terminated by or on behalf of the patient´s decision. 196 
 OIT-treatment was terminated by the study physician due to safety concerns 197 
(e.g. insufficient adherence to protocol, or recurrent gastrointestinal AEs 198 
possibly related to OIT). 199 
 200 
1.6 Health related quality of life (HRQL) measures 201 
To measure changes in health-related quality of life (HRQL) the German translation 202 
of the Food Allergy Quality of Life Questionnaire was sent out to parents (FAQLQ-203 
PF5, parental form, proxy measurement), children (FAQLQ-CF6, child form) and 204 
teenagers (FAQLQ-TF7), teenage form) 4 weeks before initial OFC and 4 weeks after 205 
final OFC. Mothers of children 3-12 years old, children 8-12 years old and teenager 206 
13-17 years old were asked to fill out the forms at home and to send them back to the 207 
study unit. FAQLQ-TFs were not included in data analysis due to the small number of 208 
teenagers in the study (active group n=1, placebo group n=5). Depending on the age 209 
of the child, the FAQLQ-PF included 26-30 items in three domains (emotional impact, 210 
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food-related anxiety, social and dietary limitations). It measured the parent’s report on 211 
the child’s HRQL from the child’s perspective. The FAQLQ-CF included 24 items in 212 
four domains (allergen avoidance, risk of accidental exposure, emotional impact, 213 
dietary restrictions). The scoring system was a 7-point Likert scale ranging from 214 
either 0 in the FAQLQ-PF or from 1 in the FAQLQ-CF (= no impact on HRQL) to 6 in 215 
the FAQLQ-PF or 7 in the FAQLQ-CF (= extreme impact on HRQL). To harmonize 216 
both scales in data analysis the raw scores 0-6 in the FAQLQ-PF were recorded as 217 
1-7, as in other studies6, 8. For comparison of changes in HRQL before and after OIT 218 
in both study groups only complete data sets were considered for analysis (PP 219 
analysis). The mean total and mean domain scores were calculated for each 220 
child/mother. 221 
 222 
2. Supplemental Results 223 
2.1 Drop outs 224 
Ten of 62 patients discontinued during the study (see FIG 1): One patient of the 225 
peanut-OIT group withdrew consent after randomization but before receiving the 226 
allocated intervention. Two patients of each randomization group discontinued due to 227 
adverse events: Within the placebo-OIT group one patient suffered from sudden 228 
abdominal pain, sleepiness, followed by rhinoconjunctivitis, vomiting and 229 
unconsciousness 75 minutes after intake of the placebo-OIT dose and 15 minutes 230 
after eating a cookie from a friend. Due to the severity of symptoms (severity grade 231 
V) this event was considered a severe adverse event (SAE) related to OIT (and thus- 232 
following the protocol- the patient had to be excluded. Another patient in the placebo-233 
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OIT group experienced a worsening of known episodes of recurrent obstructive 234 
bronchitis in the winter not related to OIT. Although the pulmonary situation stabilized 235 
after a reduction of the placebo-OIT dose the mother decided to discontinue the 236 
study. One patient of the peanut-OIT group suffered from abdominal pain, 237 
rhinoconjunctivitis, swelling of the eyes and lips, generalized hives and dry cough 238 
(severity grad III) 45 minutes after ingestion of 500 mg peanut protein-OIT during 239 
physical activity outside during the summer. After treatment with inhalant salbutamol, 240 
systemic antihistamines and steroids the patient was admitted to hospital for 241 
monitoring, and per protocol, the patient had to be excluded from the study. The 242 
patient was known to suffer from seasonal allergic rhinoconjunctivitis due to grass 243 
pollen sensitization and bronchial asthma. Prior to this event the patient had had to 244 
be down-dosed due to GI symptoms. In the winter, one patient in the peanut-OIT 245 
group experienced recurrent infections of the upper airways and coughs, 246 
rhinoconjunctivitis and shortness of breath not related to OIT. After a 50% reduction 247 
of OIT dose symptoms remained. The family decided to stop OIT. The patient was 248 
highly sensitized to house dust mite and suffered from bronchial asthma and 249 
perennial rhinoconjunctivitis before starting OIT.  250 
In the placebo-group one patient did not adhere to the study protocol;  two patients 251 
withdrew consent during the build-up phase; one patient refused to finish the OFC 252 
due to fear of allergic reactions during final oral OFC and one patient experienced a 253 
severe protocol deviation. This patient suffered from worsening of GI symptoms 254 
during the build-up phase of the placebo-OIT. Although receiving a 75%-step-down in 255 
dosing, the symptoms remained. The chocolate pudding vehicle was sent back to the 256 
study center,  where it was noticed that the patient received one charge of the wrong 257 
peanut-chocolate pudding vehicle. The investigator decided that the patient should 258 
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2.2 Safety  273 
 274 
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TABLE E2: Number of OIT doses associated with adverse events (AEs) in the 275 




Total OIT doses, n= 13,813 12,412  
OIT doses during up-dosing, n= 11,838 10,323  
OIT doses during maintenance, n= 1,975 2,089  
 
 
Number of OIT doses associated with….. 
  
p values* 
AEs in total, n= (%) 170 (1.2) 534 (4.3) .001 
Subjective AEs, n= (%) 72 (0.52) 459 (3.7) <.001 
OAS, n= (%) 29 (0.21) 281 (2.26) .003 
Abdominal pain, n= (%) 20 (0.14) 111 (0.89) <.001 
Nausea, n= (%) 8 (0.06) 13 (0.1) .07 
Skin itching, n= (%) 23 (0.17) 10 (0.1) 1.0 
Joint pain/ headache/ throat pain, n= (%) 5 (0.04) 70 (0.56) .11 
Objective AEs, n= (%) 107 (0.77) 85 (0.68) .98 
Objective AEs during up-dosing, n= (%) 99 (0.84) 81 (0.78) .99 
Objective AEs during maintenance, n= (%) 8 (0.41) 4 (0.19) .79 
Skin symptoms (contact urticarial, flush, generalized 
hives, angioedema), n= (%) 
23 (0.17) 24 (0.19) .44 
GI symptoms (vomiting, diarrhoea), n= (%) 10 (0.07) 26 (0.21) .63 
URT symptoms (conjunctivitis, rhinitis, sneezing, 
rhino-conjunctivitis), n= (%) 
58 (0.42) 10 (0.08) .64 
Laryngeal symptoms (hoarseness, stridor), n= (%) 14 (0.1) 1 (0.01) 1.0 
Lower respiratory tract symptoms (coughing, 
wheezing, shortness of breath), n= (%) 
20 (0.14) 52 (0.42) .11 
Coughing, n= (%) 15 (0.11) 41 (0.33) .09 
Wheezing, n= (%) 1 (0.01) 8 (0.06) .045 
Shortness of breath related to OIT, n= (%) 4 (0.03) 3 (0.02) .8 
Cardio-vascular symptoms (drop in blood pressure, 
unconsciousness), n= (%) 
1 (0.01) 0 (0) .33 
AEs of severity grade I, n= (%) 6 (0.04) 12 (0.1) .46 
AEs of severity grade II, n= (%) 54 (0.39) 12 (0.1) .81 
AEs of severity grade III, n= (%) 28 (0.2) 50 (0.4) .73 
AEs of severity grade IV, n= (%) 19 (0.14) 11 (0.1) .28 
AEs of severity grade V, n= (%) 1 (0.01) 0 (0) .33 
Treatment for AEs related to OIT, n= (%) 12 (0.09) 23 (0.19) .261 
Application of systemic antihistamines for AEs related 
to OIT, n= (%) 
9 (0.07) 12 (0.1) .531 
Application of systemic steroids for AEs related to OIT, 
n= (%) 
4 (0.03) 5 (0.04) .922 
Application of inhalant salbutamol for AEs related to 
OIT, n= (%) 
6 (0.04) 10 (0.08) .561 
Application of adrenalin for AEs related to OIT, n= (%) 0 (0) 0(0) 1.0 
 277 
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*p-value comparing the percentage of OIT doses associated with AEs per 278 
patient between groups using the Kruskal-Wallis test 279 
 280 
 281 
TABLE E3: Serious adverse events during placebo-/peanut-OIT 282 
 283 
Table is in landscape format, attached in extra file 284 
  285 
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2.3 Health related quality of life (HRQL)  286 
 287 
TABLE E4: Baseline median scores of FAQLQ prior to start of OIT as measure 288 
of HRQL  289 
 placebo-OIT peanut-OIT 
Parent form (FAQLQ-PF) [IQR] 




















Child form (FAQLQ-CF) [IQR] 

























Results are reported as the median [IQR] baseline scores of total and specific 290 
domains of the distributed questionnaire for HRQL (FAQLQ).  291 
PF Parent form, CF child form. *p= .035 292 
 293 
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3. Supplemental Discussion 294 
 295 
 296 
FIG E2: Maximum tolerated single dose of peanut protein prior and post OIT of     297 
patients not reaching their planned maintenance dose. 298 
Shown are the maximum tolerated single doses of peanut protein at initial and final 299 
OFC in (A) individual placebo-OIT patients not reaching the planned maintenance 300 
dose with a median maintenance dose of “32.5mg Placebo (range: 3.5- 150mg)” and 301 
(B) peanut-OIT patients not reaching the planned maintenance dose with a median 302 
maintenance dose of 50mg peanut protein (range: 2.5- 225mg) of the per protocol 303 
population. The horizontal lines represent the median of the maximum tolerated 304 
single dose in each group. For the statistical analysis of the comparison of data pre 305 
and post treatment within one randomization group, the Wilcoxon-test was used. 306 
**p<.01 307 
 308 
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TABLE E5: Characteristics of patients who tolerated a maximum dose of 309 
≥300mg peanut protein at baseline OFC 310 
Table is in landscape format, attached in extra file 311 
 312 
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Time to reaction 
after OIT dose 
Cause for SAE/ possible 
augmentation factor 
Symptoms Severity Treatment/ early termination  
placebo-
OIT 
118 4.5  75 minutes 
Possible accidental reaction 
after cookie from friend 




Antihistamine p.o., corticosteroid 
rec.  monitoring for 2 hours in 
ER  per protocol early 
termination: SAE related to OIT 
placebo-
OIT 
270 150 24 hours 
Accidental reaction after 
peanut sauce at barbeque 
OAS, angioedema, abdominal 
pain, coughing, generalized 
hives 
III 
Antihistamine p.o., corticosteroid 




106 3.5 24 hours 
Possible accidental reaction 
after mucosal contact with 
peanut/ physical activity 
Conjunctivitis, hoarseness, 
coughing, shortness of 
breath, flush 
IV 




88 20  17 hours 
Possible accidental reaction 
after eating snack 
Abdominal pain, generalized 
hives, coughing, wheezing 
IV 
Antihistamine p.o., corticosteroid 




168 1.75 16 hours 
Ingestion of raw carrot/ viral 
infection 
OAS, coughing III 
Antihistamine p.o., corticosteroid 
p.o.  hospitalization 
peanut-
OIT 
342 125 45 minutes 
Physical activity (running 




generalized hives, coughing 
III 
Inhaled Salbutamol, antihistamine 
p.o., corticosteroid  i.v. 
hospitalization 
 per protocol early termination: 




230 4.5 3.5 hours 
Possible accidental reaction 
after Chinese meal/ URI 
Coughing, somnolence V 
Adrenaline i.m., antihistamine p.o., 
corticosteroid rec. 
hospitalization 
Repository E Table E3
 p.o. (per os), i.v. (intravenous), i.m. (intramuscular), rec. (rectal), URI (upper respiratory infection), OAS (oral allergy syndrome), 
emergency room (ER) 
*defined as adverse events that were leading to death, hospitalization, disability, were life-threatening or otherwise deemed an 
important medical event 
peanut-
OIT 
15 1  23 hours  
Possible accidental reaction 
after Sushi meal 
OAS, coughing, allergic 
rhinoconjunctivitis, itching 
III 
Antihistamine i.v., corticosteroid 
i.v. hospitalization 



































dose *at  



























#5 placebo   300mg 7.5 1.08 0.02 “250mg” 4,500mg +0.5 +0.79 +0.05 0 1 
#28 placebo 1,000mg 5 1.02 ND “250mg” 1,000mg +3.5 -0.53 ND 0 1 
#53 placebo   300mg 7 7.79 0.1 “150mg”   300mg +3 -1.7 -0.03 0 0 
#62 placebo   300mg 7.5 93.8 1.22 “250mg” 1,000mg -2.5 -50.4 -0.3 0 1 
#1 peanut 1,000 mg 5 4.1 0.11 250mg 4,500mg +0.5 -1.09 +0.43 0 0 
#2 peanut 3,000mg 3 2.21 0.01 250mg 4,500mg +4.5 -0.15 +0.03 0 0 
#7 peanut    300mg 5.5 68.9 1.39 250mg 4,500mg -2.5 -20.2 +0.52 0 0 
#16 peanut    300mg 6 1.86 0.05 250mg 1,000mg +2.5 -0.27 -0.01 1 0 
#29 peanut   1000mg 8 0.98 0.02 225mg 4,500mg -4.5 -0.55 +0.17 0 0 
#46 peanut    300mg 7 40.2 0.62 250mg 4,500mg +1 +10.9 +4.7 0 0 
#50 peanut 3,000mg 6 1.63 0.2 225mg 4,500mg -6 -1.02 +1.17 0 0 
#55 peanut   300mg 9 0.57 1.32 250mg 4,500mg -6.5 +0.86 -0.43 0 0 
#64 peanut   300mg 8.5 3.15 0.07 250mg 4,500mg -4 -2.15 -0.05 0 0 
#69 peanut 3,000mg 9.5 0.63 ND 250mg 4,500mg -4.5 +1.41 ND 0 0 
Repository E Table E5
*   Dose of peanut protein 
** “Delta” represents the change from baseline to post treatment (post-OIT value minus pre-OIT value) 
